↓ Skip to main content

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

Overview of attention for article published in BMC Cancer, May 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
7 tweeters

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
32 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
Published in
BMC Cancer, May 2009
DOI 10.1186/1471-2407-9-145
Pubmed ID
Authors

Justin M Balko, Esther P Black

Abstract

The anti-EGFR monoclonal antibody cetuximab is used in metastatic colorectal cancer (CRC), and predicting responsive patients garners great interest, due to the high cost of therapy. Mutations in the KRAS gene occur in ~40% of CRC and are a negative predictor of response to cetuximab. However, many KRAS-wildtype patients do not benefit from cetuximab. We previously published a gene expression predictor of sensitivity to erlotinib, an EGFR inhibitor. The purpose of this study was to determine if this predictor could identify KRAS-wildtype CRC patients who will benefit from cetuximab therapy.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 6%
United States 1 3%
Unknown 29 91%

Demographic breakdown

Readers by professional status Count As %
Other 7 22%
Student > Ph. D. Student 5 16%
Student > Bachelor 4 13%
Researcher 4 13%
Student > Master 4 13%
Other 7 22%
Unknown 1 3%
Readers by discipline Count As %
Medicine and Dentistry 15 47%
Biochemistry, Genetics and Molecular Biology 5 16%
Agricultural and Biological Sciences 5 16%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Business, Management and Accounting 1 3%
Other 4 13%
Unknown 1 3%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2015.
All research outputs
#1,768,337
of 8,578,222 outputs
Outputs from BMC Cancer
#428
of 3,557 outputs
Outputs of similar age
#1,694,125
of 7,970,558 outputs
Outputs of similar age from BMC Cancer
#428
of 3,555 outputs
Altmetric has tracked 8,578,222 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,557 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 7,970,558 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 3,555 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.